Actelion shareholders had approved this stock split at their Annual General Meeting on 4 May 2007. The relevant listing notice will be published in the Swiss Commercial Gazette (Schweizerisches Handelsamtsblatt), NZZ (Neue Zürcher Zeitung) as well as Le Temps on 5 June 2007.

Statement for the record on concluded share buy back program

On 9 November 2006, Actelion announced its intention to repurchase own shares worth up to CHF 48 million in the open market to mitigate dilution arising from the 2008 convertible bond. Actelion has now formally completed this specific share repurchase program. In total, the company has repurchased 129’275 of its registered shares for an amount of CHF 35 million.

###

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland.  Actelion's first drug Tracleer^®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer^® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland.  At the end of September 2006, Tracleer^® was commercially available in 35 countries worldwide. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. Actelion’s over 1,200 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs.  Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact:

Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil